ConcertAI has inked a deal with Memorial Sloan Kettering Cancer Center to accelerate the development and deployment of clinical AI algorithms.
Under the multiyear strategic agreement, Memorial Sloan Kettering will use AI software-as-a-service (SaaS) technology from ConcertAI's Eureka Life Science AI Platform, powered by TeraRecon. The technology will be used to build, test, and deploy new models for tumor detection, segmentation, classification, and cancer treatment response, ConcertAI said.
The end goal for both organizations is to improve the speed, precision, and generalizability of AI models to allow more patients, trials, and institutions to benefit from the technology, the company added.
